Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

Trial Details

NCT ID
NCT06592599
Phase
PHASE2
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Toripalimab
  • Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Eligible disease(s) / stage(s): Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8
  • Prior therapy: None for NPC permitted
  • Life expectancy: 3 months at least
  • Contraception requirements: Women of childbearing potential and male participants who are sexually active must agree to use a medically effective m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →